深圳市禾沐基因生物技术

Hemu Gene is a clinical-stage biotechnology company headquartered in Shenzhen, China, dedicated to developing curative gene therapies for rare genetic disorders. The company leverages a proprietary hematopoietic stem cell (HSC) gene-editing platform, utilizing CRISPR/Cas9 and base editing technologies to address unmet medical needs in hematology. Its lead program, HM-GT-001, is an autologous gene-edited cell therapy currently in Phase 1/2 clinical trials for the treatment of transfusion-dependent beta-thalassemia. By targeting the BCL11A erythroid enhancer, the therapy aims to restore functional hemoglobin levels and eliminate the need for chronic blood transfusions. Hemu Gene is supported by prominent venture capital firms and maintains integrated R&D and GMP manufacturing facilities to accelerate its pipeline development.